Developer docs
API playgroundTry for free, no card

Search company profiles

NexMR

Full company profile

uuid0005y6h

Namestring
NexMR
Legal namestring
NexMR
Websiteurl
nexmr.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

NexMR is an ETH Zurich spin-off that develops, manufactures, and sells ultrafast NMR technology targeting pharmaceutical and biotechnology drug discovery customers. The company's platform addresses a bottleneck in NMR-based fragment screening — slow measurement turnaround and high cost — by combining proprietary light-coupled NMR hardware with automated analysis software and consumables for sample preparation. Technical building blocks include light-sources for high-field NMR, light-coupled benchtop NMR spectrometers, a pre-optimized fragment library, a reagents kit, and two software modules (automated screening analysis and automated affinity determination via isotope labeling). The core scientific differentiator is a photo-CIDNP NMR fragment screening technique published in JACS, which the company claims enables 30-50-fold faster measurements and 10-100-fold lower sample concentration requirements relative to traditional high-field NMR workflows.

The company sells a fully integrated workflow of hardware, consumables, and software through a consultative, sales-led direct motion. Customers submit applications via the NexMR website and receive a customized proposal within 1-2 business days. Pricing is not publicly disclosed and is provided on a quote basis. Revenue streams are diverse across the three product lines: hardware sales (light-sources and benchtop NMR instruments), consumables (fragment library and reagents kit), and one-time software licenses for the analysis modules. The Go-to-market leverages scientific publications in peer-reviewed journals (JACS, Angewandte Chemie), industry coverage (Practical Fragments), and presence at NMR-focused conferences (EUROMAR, SCS Fall Meeting) to build credibility with pharmaceutical R&D buyers.

Founded by Dr Félix Torres (CEO, PhD Chemistry ETH Zurich), Dr Matthias Bütikofer (CSO, MSc Chemistry ETH Zurich, ex-Roche), and advised by Prof Roland Riek (tenured ETH Zurich professor, pioneer in biomolecular NMR), NexMR is headquartered in Schlieren, Switzerland. The company has secured CHF 150,000 in grant funding from Venture Kick, established strategic partnerships with CrystalsFirst and Chemspace, and validated its technology on a Bruker benchtop NMR platform. Its primary customer segment is pharmaceutical and biotech companies conducting early-stage drug discovery, with use cases spanning hit identification, fragment screening, and binding affinity determination.

Short descriptiontext

NexMR is an ETH Zurich spin-off that provides ultrafast NMR technology for drug discovery, including light-coupled benchtop NMR hardware, consumables, and automated analysis software delivering 30-50-fold faster measurements for pharmaceutical and biotech customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NMR fragment screening, drug discovery technology, benchtop NMR hardware, NMR consumables reagents, NMR data analysis software
Industry1 code
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
NMR Spectroscopy Equipment for Drug Discovery
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1NMR Hardware Sales
TypeHardware Sales
Description

Sale of light-sources for high-field NMR systems and light-coupled benchtop NMR spectrometers as core hardware products

nexmr.com
2Consumables
TypeHardware Sales
Description

Ultrafast NMR Fragment library and reagents kit providing recurring consumable revenue for NMR screening workflows

nexmr.com
3Software Licenses
TypeOne Time License
Description

Automated screening analysis and affinity determination analysis software, likely sold as licenses or subscriptions

nexmr.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NexMR provides an Ultrafast NMR Technology platform for drug discovery, combining light-coupled benchtop NMR hardware, specialized consumables (fragment library and reagents kit), and automated analysis software. The offering enables 30-50-fold faster NMR measurements, 10-100-fold reduced sample concentration requirements, and atomic-scale structural information for pharmaceutical R&D applications. As an ETH Zurich spin-off, NexMR delivers key-in-hand solutions to improve throughput and optimize resources of NMR-drug discovery pipelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30-50-fold faster NMR measurements
+2 more records
Product overview1 text field

NexMR offers a unified platform of ultrafast NMR technology for drug discovery, consisting of three integrated product lines: (1) Hardware including light-sources for high-field NMR and light-coupled benchtop NMR spectrometers that enable 100-fold faster measurements; (2) Consumables including the Ultrafast NMR Fragment library and Ultrafast NMR reagents kit that reduce sample preparation time; and (3) Software for automated screening analysis and automated affinity determination analysis that enables ultrafast, automated data processing. The platform is designed to address challenging drug discovery targets by providing sensitivity-enhanced NMR with 30-50-fold faster results, compatibility with benchtop systems, and reduced sample concentration requirements of 10-100-fold. NexMR is an ETH Zurich spin-off offering key-in-hands solutions to improve NMR-drug discovery pipeline throughput.

Product and service6 records
1Light-coupled benchtop NMR
CategoryHardware
Description

Light-coupled benchtop NMR hardware that enables 100-fold faster NMR measurements through light-source technology, designed to be compatible with benchtop NMR systems. Targets pharmaceutical and biotech researchers conducting fragment screening.

2Light-sources for high-field NMR
CategoryHardware
Description

High-field NMR light-sources that are part of NexMR's ultrafast NMR technology portfolio, enabling enhanced sensitivity for NMR measurements in drug discovery workflows.

3Ultrafast NMR Fragment library
CategoryConsumables
Description

A pre-designed library of NMR fragments for screening applications, part of NexMR's consumables portfolio designed to reduce NMR sample preparation time for drug discovery workflows.

4Ultrafast NMR reagents kit
CategoryConsumables
Description

Reagent kit for ultrafast NMR analysis that optimizes performance and reduces sample preparation time for NMR-based drug discovery workflows.

5Automated screening analysis software
CategorySoftware
Description

Automated data analysis software for NMR fragment screening, enabling ultrafast processing of screening results for drug discovery researchers.

6Automated affinity determination analysis software
CategorySoftware
Description

Software for automated determination of binding affinities through NMR analysis using isotope labeling, enabling quantitative assessment of molecular interactions for drug discovery teams.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic collaboration between NexMR and Chemspace to expand access to fragment screening services and chemical libraries. Chemspace provides extensive chemical compound sourcing capabilities complementing NexMR's NMR screening technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-24
Description

NexMR and CrystalsFirst announced a partnership to combine their respective technologies for enhanced fragment screening capabilities in drug discovery. CrystalsFirst provides crystal-based screening expertise while NexMR contributes ultrafast NMR technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NexMR

NMR Spectroscopy Equipment for Drug Discoverynexmr.com

NexMR is an ETH Zurich spin-off that provides ultrafast NMR technology for drug discovery, including light-coupled benchtop NMR hardware, consumables, and automated analysis software delivering 30-50-fold faster measurements for pharmaceutical and biotech customers.

What NexMR does

NexMR is an ETH Zurich spin-off that develops, manufactures, and sells ultrafast NMR technology targeting pharmaceutical and biotechnology drug discovery customers. The company's platform addresses a bottleneck in NMR-based fragment screening — slow measurement turnaround and high cost — by combining proprietary light-coupled NMR hardware with automated analysis software and consumables for sample preparation. Technical building blocks include light-sources for high-field NMR, light-coupled benchtop NMR spectrometers, a pre-optimized fragment library, a reagents kit, and two software modules (automated screening analysis and automated affinity determination via isotope labeling). The core scientific differentiator is a photo-CIDNP NMR fragment screening technique published in JACS, which the company claims enables 30-50-fold faster measurements and 10-100-fold lower sample concentration requirements relative to traditional high-field NMR workflows.

The company sells a fully integrated workflow of hardware, consumables, and software through a consultative, sales-led direct motion. Customers submit applications via the NexMR website and receive a customized proposal within 1-2 business days. Pricing is not publicly disclosed and is provided on a quote basis. Revenue streams are diverse across the three product lines: hardware sales (light-sources and benchtop NMR instruments), consumables (fragment library and reagents kit), and one-time software licenses for the analysis modules. The Go-to-market leverages scientific publications in peer-reviewed journals (JACS, Angewandte Chemie), industry coverage (Practical Fragments), and presence at NMR-focused conferences (EUROMAR, SCS Fall Meeting) to build credibility with pharmaceutical R&D buyers.

Founded by Dr Félix Torres (CEO, PhD Chemistry ETH Zurich), Dr Matthias Bütikofer (CSO, MSc Chemistry ETH Zurich, ex-Roche), and advised by Prof Roland Riek (tenured ETH Zurich professor, pioneer in biomolecular NMR), NexMR is headquartered in Schlieren, Switzerland. The company has secured CHF 150,000 in grant funding from Venture Kick, established strategic partnerships with CrystalsFirst and Chemspace, and validated its technology on a Bruker benchtop NMR platform. Its primary customer segment is pharmaceutical and biotech companies conducting early-stage drug discovery, with use cases spanning hit identification, fragment screening, and binding affinity determination.

NexMR firmographics

Firmographics
Name
NexMR
Legal name
NexMR
Website
https://nexmr.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
NexMR is an ETH Zurich spin-off that provides ultrafast NMR technology for drug discovery, including light-coupled benchtop NMR hardware, consumables, and automated analysis software delivering 30-50-fold faster measurements for pharmaceutical and biotech customers.
Ownership category
akta.pro rank

NexMR industry classification

Industry
Product category
NMR Spectroscopy Equipment for Drug Discovery
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • NMR fragment screening
  • Drug discovery technology
  • Benchtop NMR hardware
  • NMR consumables reagents
  • NMR data analysis software

Where NexMR is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

NexMR business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. NMR Hardware Sales: Sale of light-sources for high-field NMR systems and light-coupled benchtop NMR spectrometers as core hardware products
  2. Consumables: Ultrafast NMR Fragment library and reagents kit providing recurring consumable revenue for NMR screening workflows
  3. Software Licenses: Automated screening analysis and affinity determination analysis software, likely sold as licenses or subscriptions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NexMR product offering

Product offering

Core offering

NexMR provides an Ultrafast NMR Technology platform for drug discovery, combining light-coupled benchtop NMR hardware, specialized consumables (fragment library and reagents kit), and automated analysis software. The offering enables 30-50-fold faster NMR measurements, 10-100-fold reduced sample concentration requirements, and atomic-scale structural information for pharmaceutical R&D applications. As an ETH Zurich spin-off, NexMR delivers key-in-hand solutions to improve throughput and optimize resources of NMR-drug discovery pipelines.

Product overview

NexMR offers a unified platform of ultrafast NMR technology for drug discovery, consisting of three integrated product lines: (1) Hardware including light-sources for high-field NMR and light-coupled benchtop NMR spectrometers that enable 100-fold faster measurements; (2) Consumables including the Ultrafast NMR Fragment library and Ultrafast NMR reagents kit that reduce sample preparation time; and (3) Software for automated screening analysis and automated affinity determination analysis that enables ultrafast, automated data processing. The platform is designed to address challenging drug discovery targets by providing sensitivity-enhanced NMR with 30-50-fold faster results, compatibility with benchtop systems, and reduced sample concentration requirements of 10-100-fold. NexMR is an ETH Zurich spin-off offering key-in-hands solutions to improve NMR-drug discovery pipeline throughput.

Differentiator

Problem solved

Functional benefit

Products and services

  • Light-coupled benchtop NMR Light-coupled benchtop NMR hardware that enables 100-fold faster NMR measurements through light-source technology, designed to be compatible with benchtop NMR systems. Targets pharmaceutical and biotech researchers conducting fragment screening.
  • Light-sources for high-field NMR High-field NMR light-sources that are part of NexMR's ultrafast NMR technology portfolio, enabling enhanced sensitivity for NMR measurements in drug discovery workflows.
  • Ultrafast NMR Fragment library A pre-designed library of NMR fragments for screening applications, part of NexMR's consumables portfolio designed to reduce NMR sample preparation time for drug discovery workflows.
  • Ultrafast NMR reagents kit Reagent kit for ultrafast NMR analysis that optimizes performance and reduces sample preparation time for NMR-based drug discovery workflows.
  • Automated screening analysis software Automated data analysis software for NMR fragment screening, enabling ultrafast processing of screening results for drug discovery researchers.
  • Automated affinity determination analysis software Software for automated determination of binding affinities through NMR analysis using isotope labeling, enabling quantitative assessment of molecular interactions for drug discovery teams.

Quantifiable outcome

  • 30-50-fold faster NMR measurements
  • +2 more outcomes

Companies that use NexMR

Customer profile

Segments1 record

Ideal customer profiles1 record

NexMR technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

NexMR partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ChemspacecoreStrategic or Co-development Partner · 1 January 2024Strategic collaboration between NexMR and Chemspace to expand access to fragment screening services and chemical libraries. Chemspace provides extensive chemical compound sourcing capabilities complementing NexMR's NMR screening technology.
  • CrystalsFirstcoreStrategic or Co-development Partner · 24 July 2023NexMR and CrystalsFirst announced a partnership to combine their respective technologies for enhanced fragment screening capabilities in drug discovery. CrystalsFirst provides crystal-based screening expertise while NexMR contributes ultrafast NMR technology.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

NexMR competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NexMR financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NexMR leadership team

Management profile

Number of profiles

Profiles4 records

NexMR funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NexMR M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NexMR

What does NexMR do?

NexMR provides an Ultrafast NMR Technology platform for drug discovery, combining light-coupled benchtop NMR hardware, specialized consumables (fragment library and reagents kit), and automated analysis software. The offering enables 30-50-fold faster NMR measurements, 10-100-fold reduced sample concentration requirements, and atomic-scale structural information for pharmaceutical R&D applications. As an ETH Zurich spin-off, NexMR delivers key-in-hand solutions to improve throughput and optimize resources of NMR-drug discovery pipelines.

Is NexMR a public or private company?

NexMR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NexMR founded?

NexMR was founded in 2021. It employs 1 to 10 people.

Where is NexMR based?

NexMR is headquartered in Schlieren, Switzerland, in the Europe region.

How does NexMR make money?

Three revenue lines are on record. NMR Hardware Sales are the primary driver. The others are consumables and software Licenses.

Does NexMR have an API?

No public API is recorded for NexMR.

What industry is NexMR in?

NexMR's product category is NMR Spectroscopy Equipment for Drug Discovery. Its primary akta.pro industry code is HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNexMR Joins the Magritek Group to Push Benchtop NMR One Step FurtherNexMR, a developer of photohyperpolarization technology, joined Magritek, the global leader in benchtop NMR instrumentation. The integration brings photohyperpolarization into Magritek's Spinsolve platform, making NMR biophysics accessible from the benchtop. Development of the first hyperpolarization-enabled systems is underway, with availability expected within 12 months.News-MedicalRevolutionizing drug discovery: High-throughput fragment screening with NexMR's X-Pulse benchtop NMR spectrometerThe article describes NexMR's high-throughput fragment screening technology using Oxford Instruments' X-Pulse benchtop NMR spectrometer, which employs photo-induced signal enhancement to reduce screening time from over 100 hours to approximately two minutes. The technology successfully detected micromolar concentrations and fragment-protein binding events against targets including PIN1 and KRAS oncoproteins, demonstrating reliable signal-to-noise ratios in automated screening workflows. This technical capability enables pharmaceutical researchers to accelerate drug development through small-footprint, cryogen-free benchtop NMR systems.Venture KickCHF 40,000 for a NMR-based fragment screening platform and miniature sensors in the EVDNexMR and Rhovica Neuroimaging have secured CHF 40,000 in financial support from Venture Kick to advance their technologies aimed at addressing unmet medical needs. NexMR is developing an NMR-based fragment screening platform to enhance drug discovery, while Rhovica Neuroimaging is integrating miniature sensors into external ventricular drains to improve neurosurgical procedures and reduce complications. Both companies plan to finalize their prototypes and begin early marketing efforts as part of their development.